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Abstract
Background: Better treatments for schizophrenia are urgently needed. The therapeutic use of the nitric oxide (NO)-donor
sodium nitroprusside (SNP) in patients with schizophrenia has shown promising results. The role of NO in schizophrenia is
still unclear, and NO modulation is unexplored in ketamine (KET) animal models to date. In the present study, we compared
the behavioral effects of pre- and post-treatment with SNP, glyceryl trinitrate (GTN), and methylene blue (MB) in the acute
KET animal model of schizophrenia.
The present study was designed to test whether acute SNP, GTN, and MB treatment taken after (therapeutic effect) or before
(preventive effect) a single KET injection would influence the behavior of rats in the sucrose preference test, object
recognition task and open field.
Results: The results showed that KET induced cognitive deficits and hyperlocomotion. Long- term memory improvement
was seen with the therapeutic GTN and SNP treatment, but not with the preventive one. MB pretreatment resulted in
long-term memory recovery. GTN pre-, but not post-treatment, tended to increase vertical and horizontal activity in the
KET model. Therapeutic and preventive SNP treatment consistently decreased KET-induced hyperlocomotion.
Conclusion: NO donors – especially SNP – are promising new pharmacological candidates in the treatment of
schizophrenia. In addition, we showed that the potential impact of NO-related compounds on KET-induced behavioral
changes may depend on the temporal window of drug administration.
Keywords: Sodium nitroprusside, Glyceryl trinitrate, Methylene blue, Ketamine model, Schizophrenia, Therapeutic
treatment, Preventive treatment
Background
Schizophrenia treatment represents a major challenge. We
have recently reported in a randomized, placebo-controlled
trial, a safe, rapid, and long-lasting improvement of positive,
negative, anxiety, and depressive symptoms in patients with
schizophrenia after a single intravenous injection of the nitric
oxide (NO) donor sodium nitroprusside (SNP) [1]. SNP was
also effective in clozapine-refractory schizophrenia [2]. In the
rat model of schizophrenia using phencyclidine (PCP) injec-
tion, pretreatment with SNP abolished behavioral changes
associated with positive symptoms, such as hyperactivity and
stereotyped behavior [3]. Although no alterations in prepulse
inhibition (PPI) of the acoustic startle response after SNP
treatment have been reported in naïve rats [4], a recent study
showed that SNP increased PPI response in naïve mice, and
SNP pretreatment blocked PPI disruption induced by am-
phetamine [5].
Despite contradictory results in PPI when analyzed in rats
or in mice, SNP produced an unequivocal improvement in
schizophrenic patients [1,2] and in animal models [3,5]. The
exact antipsychotic mechanism of action of SNP is unclear,
but it may act through the glutamate N-methyl-D-aspartate
(NMDA) receptor-NO-cyclic guanosine monophosphate
(cGMP) pathway, which is altered in schizophrenia [6]. In
addition, there is evidence of interaction between SNP/NO
and the dopaminergic system [7,8].
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Glyceryl trinitrate (GTN) is another NO donor. Unlike
SNP, which once in the blood stream dissociates immediately
and releases NO [9], GTN is able to react with reduced
thiols, cysteine derivatives, ascorbate and mitochondrial alde-
hyde dehydrogenase, yielding bioactive nitrites and NO [10].
On the other hand, methylene blue (MB), a phenothiazine
compound routinely used to inhibit soluble guanylate cyclase
(sGC) and isoforms of NO synthase (NOS), inactivates NO
by generation of superoxide anions [11]. Interestingly, MB
pretreatment shows antipsychotic-like properties in the MK-
801 mouse model [12].
Sub-anesthetic doses of ketamine (KET), a non-
competitive NMDA receptor antagonist, elicit positive
and negative symptoms, and cognitive deficits in
humans [13] and animal models [14,15]. Single or re-
peated KET administration induces changes in systems
involving glutamate, dopamine, serotonin and gamma-
aminobutyric acid (GABA), neurotransmitters implicated in
schizophrenia pathophysiology [16]. Glutamate and dopa-
mine altered neurotransmission are particularly involved in
positive and negative symptoms, and in cognitive deficits
observed in schizophrenia [17], which makes the acute
KET model useful for explaining this impairments [15].
The role of NO in schizophrenia is complex and still un-
clear. Antipsychotic-like properties have been demon-
strated in animal models using either pretreatment with
NO donors [3,5] or with NO inhibitors [12,18]. NO
modulation is unexplored in KET animal models to date,
although hippocampal increase of NADPH-diaphorase
stained neurons with no changes in neuronal NOS expres-
sion has been reported in the sub-chronic KET rat model
[14]. In the present study, we compared the behavioral ef-
fects of pre- and post-treatment with SNP, GTN or MB in
the acute KET animal model of schizophrenia.
Methods
Animals
The procedures followed guidelines from the Brazilian Coun-
cil for Control of Animal Experimentation, and were ap-
proved by our local Commission for Ethics in Animal
Experimentation (University of Sao Paulo School, Ribeirao
Preto School of Medicine; protocol #102/2012). We used
2 month-old male Wistar rats weighing 250-280 g at the be-
ginning of the experiments. Rats were housed in pairs within
standard plastic cages before the beginning of the experi-
ments for 1 week after arriving in our facility, and alone dur-
ing the period when the sucrose preference test was
performed, as detailed bellow. Animals had free access
to food and water. The colony room was maintained at 21-
24°C and on a 12 h:12 h light-dark cycle (lights on at 7 a.m.).
Drugs and experimental timeline
Twelve groups of rats (n = 12 to 14 per group, total of
150) were formed according to the injection scheme
showed in Figure 1. A maximum of 12 animals (~3 per
group) were handled in each 72 hours of experiment in
order to assure that all initial injections occurred be-
tween 8 and 9 a.m. and that subsequent behavioral tests
happened within a very similar time window. Saline
(0.9% w/v, Isofarma, Eusebio, Brazil) was administered
intraperitoneally (i.p.) in a volume of 0.1 ml/100 g body
weight. KET (30 mg/kg, Ketamin S(+), Cristalia, Itapira,
Brazil) was administered i.p. in a volume of 1 ml/100 g
body weight (dose based on Keilhoff et al. [14]). GTN
(10 mg/kg, Tridil, Cristalia, Itapira, Brazil) was adminis-
tered i.p. in a volume of 0.1 ml/100 g body weight (dose
based on Pardutz et al. [19]). SNP (5 mg/kg, Nitropruss,
Cristalia, Itapira, Brazil) was administered i.p. in a vol-
ume of 0.1 ml/100 g body weight (dose based on Bujas-
Bobanovic et al. [3]), protected from light until injection.
MB (4 mg/kg, Azul de Metileno P.A., Synth, Diadema,
Brazil) was administered i.p. in a volume of 0.4 ml/100 g
body weight (dose based on Riha et al. [20]). KET was
freshly dissolved in saline before each experiment. GTN
and SNP were freshly dissolved in 5% (w/v) glucose solu-
tion (Isofarma, Eusebio, Brazil) before each experiment.
MB was freshly dissolved in milliQ water.
Initially, 4 groups were injected with saline at time 0 and
treated with saline, GTN, SNP or MB 30 minutes later
(Figure 1, yellow boxes). Four other groups were injected
with KET at time 0, and post-treated with saline, GTN, SNP
or MB 30 minutes later (Figure 1, green boxes). Four other
groups were pretreated with saline, GTN, SNP or MB at
time 0 and then injected with KET 30 minutes later (Figure 1,
light red boxes). Behavioral tests started 15 minutes after the
last injection, as shown in Figure 1. Intervals between injec-
tions were defined based on the assumption that we planned
to treat the ketamine injected animals during the peak of
their positive-like symptoms manifestation, which occurs
around 30 minutes after ketamine injection. In consequence,
groups on the therapeutic scheme (Figure 1, green boxes)
were evaluated (in the open field, for instance) right after this
peak, while the groups on the preventive scheme (Figure 1,
light red boxes) were still under the acute effect of ketamine.
Even though groups on the therapeutic and on the prevent-
ive scheme were not in the exactly same time window during
open field evaluation, they were both equally under the most
prominent effects of ketamine: cognitive deficits and corre-
lates of positive symptoms (please see more details in
Results).
Behavioral tests
Sucrose preference
Preference was examined by placing one animal per cage for
72 h with free access to food and with two identical gradu-
ated water bottles randomly allocated in the cage (changed
after each 24 h), one containing 250 ml of tap water and the
other 250 ml of 1% w/v sucrose (Synth, Diadema, Brazil) in
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tap water. The final volume of each bottle was measured at
the end of 24 hours, during 3 consecutive days. Total fluid
intake during 72 h in all groups was not different from SAL
+ SAL (Kruskal-Wallis Dunn’s Q< 2.124, p > 0.06) or among
all groups (Kruskal-Wallis Dunn’s Q< 3.160, p > 0.05). Thus,
sucrose preference was calculated as the ratio of sucrose in-
take to total fluid intake and values converted to percentage.
Anhedonia, an important component of depressive symp-
toms, can be assessed in rats by the loss of preference of
sweetened water over regular water [21]. In schizophrenia,
anhedonia is part of the negative and mood symptoms ad-
mixture [22].
Object recognition
The object recognition task was performed as described else-
where [23]. In brief, 20 min habituation with no objects in
the arena took place 65 min after the first injection. The next
day, training (interaction with two identical objects during
5 minutes) and a test phase 30 min later (one of the objects
was replaced by a new object with different shape) occurred
24 hours after the first injection. The following day, 48 hours
after the first injection, a “late test phase” was performed,
where the animal was allowed to explore one object known
since the training phase and a different new one (different
from the new object presented in the test phase). A rat was
always placed into the center of the arena. Measurements of
interaction with each of the objects were taken. Percentage
of time spent in exploring the new as compared with the fa-
miliar object was used. After each session, the arena and ob-
jects were cleaned thoroughly with 20% ethanol to ensure
that behavior of the rats was not guided by odor cues. The
new object recognition task is sensitive to disruption by
NMDA receptor antagonists with good predictive validity,
and it is useful to access cognitive dysfunction in schizophre-
nia models [24].
Open field
Locomotor activity was monitored for 20 minutes within an
open-field square arena (46 × 46 cm) with a white floor
bounded by transparent acrylic walls (Insight, Ribeirao Preto,
Brazil). Infrared motion sensors recorded the locomotion
and non-ambulatory activities (rearing: upward motion either
with forepaws in contact with the wall or freestanding and
measured as number of attempts), and the values were aver-
aged in 4 min blocks or shown as total scores over 20 min.
Velocity was also measured and yielded similar results (data
not shown) as those for distance. Changes in locomotion pat-
terns in the open field, like hyperactivity (increased vertical
and horizontal activity) are commonly interpreted as
psychotic-like behaviors [25]. Measures of anxiety-like behav-
ior included the relative proportion of trajectory spent ex-
ploring the center quadrants relative to those located
adjacent to the walls of the arena [26]. The open field arena
was divided-by black lines-into 64 squares of 5.75 × 5.75 cm.
The central 16 squares were defined as the central zone.
Symptoms of anxiety are a central feature of schizophrenia
since its characterization [22]. Rats were tested only once on
the open field task, and were initially placed into the center
of the arena.
Data analysis
Data were analyzed using the statistical program SigmaPlot
(version 11) and SPSS (version 19). Groups were compared
using analysis of variance (one-way ANOVA, with Bonfer-
roni post hoc test) or Student T test for variables with nor-
mal distribution, and Kruskal-Wallis Analysis of Variance
on Ranks (with Dunn post hoc test) or Mann-Whitney
Rank Sum Test for variables without normal distribution.
Statistical significance was set at p < 0.05, and values pre-
sented as mean ± standard error of mean.
Results
Sucrose preference test
Significant signs of anhedonia were not detected in con-
trol animals after GTN, SNP or MB injection, except for
an increase in sucrose consumption in SAL + GTN com-
pared to SAL +MB in the first 24 h (Q = 3.275, p < 0.05;
Figure 2A). In the KET model, therapeutic treatment
Figure 1 Timeline of the experimental procedures. Times depicted represent the beginning of each event with regard to time 0.
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with GTN (Q = 2.731, p < 0.05; Figure 2B) and MB (Q =
2.674, p < 0.05) resulted in anhedonia in the first 24 h
when compared to KET + SAL. Pretreatment (Figure 2C)
with GTN, SNP or MB did not result in anhedonia in
the KET model.
Object recognition task
Control animals injected with SNP (Q = 2.857, p < 0.05)
and MB (Q = 2.873, p < 0.05) showed impaired short
term object recognition memory (Figure 3A). Compared
to SAL + SAL, animals submitted to the KET model pre-
sented with significant impaired short term (T < 5.259, p
< 0.001; hash signs in Figure 3B and C), and impaired
long term object recognition memory (T < 3.802, p <
0.001; hash signs in Figure 3E and F). Recovery in long
term memory was seen in KET animals post-treated with
GTN (F = 3.380, p = 0.01; Figure 3E) and with SNP (a
trend, p = 0.05), but not on those pretreated. Long term
memory improvement was seen in KET animals pre-
treated with MB (F = 3.353, p = 0.03; Figure 3F), but not
on those post-treated.
Open field test
KET induced an acute anxiolytic effect, probably due to
its antidepressant properties, since KET + SAL and SAL
+ KET animals spent increased proportion of their open
field trajectory in the center when compared to SAL +
SAL (T < -2.180, p < 0.04; hash signs in Figure 4B and
C). No additional anxiolytic effect of GTN, SNP or MB
was seen. Control animals injected with SNP showed de-
creased vertical activity when compared to SAL + SAL
(Q = 2.913, p < 0.05; Figure 4D). Therapeutic treatment
with SNP of KET-injected animals also resulted in de-
creased vertical activity (Q = 3.026, p < 0.05; Figure 4E).
KET +MB showed increased vertical activity when com-
pared to KET + SNP (Q = 3.533, p < 0.05). Preventive
treatment had no effect, although GTN pretreatment re-
sulted in an apparent increase in the total number of
rearing, an indication of possible stimulant effect
(Figure 4F).
Horizontal ambulation decreased in control animals
treated with SNP only during the first 4 min of the open
field test (Q > 2.753, p < 0.05; Figure 4G). KET-injected
animals presented with hyperlocomotion during all time
points of the open field test when compared to SAL +
SAL (T < -3.721, p < 0.003; hash signs in Figure 4H and
I). Therapeutic treatment with SNP in KET-injected ani-
mals reverted KET-induced hyperlocomotion (F > 2.895,
p < 0.04; Figure 4H). Similarly, pretreatment with SNP
prevented KET-induced hyperlocomotion (F > 7.807, p <
0.03; Figure 4I). Interestingly, while GTN therapeutic
treatment of KET-injected animals tended to reduce
locomotion, GTN preventive treatment increased hyper-
locomotion, although not statistically significant when
compared to SAL + KET.
Discussion
Besides reinforcing the role of NO donors – especially SNP
– as promising new pharmacological candidates in the treat-
ment of schizophrenia, the present results also assessed for
the first time the potential impact of pre- versus post-
treatment with these drugs in the KET model. Subtle differ-
ences where seen when comparing therapeutic and prevent-
ive SNP treatment, and different outcomes in GTN post-
treatment and pretreatment. Therapeutic and preventive
treatments lead to similar results in several animal models of
neurologic disorders. Some examples include the use of MB,
retinoic acid, and cyclophosphamide in animal models of
Alzheimer’s disease and Parkinson’s disease, ischemia, and
Guillain Barrè syndrome [27-30]. By contrast, other drugs do
Figure 2 Percentage of sucrose solution consumption over a
72 hours period. There was an increase in sucrose consumption in
SAL + GTN compared to SAL +MB (€: p < 0.05) in the first 24 h in
control animals (A). In the KET model, therapeutic treatment (B)
with GTN (¥: p < 0.05) and MB (¢: p < 0.05) resulted in anhedonia in
the first 24 h. Preventive treatment (C) did not result in significant
anhedonia. Values presented as mean ± standard error of mean.
N = 12 to 14 on each group.
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not exhibit the same effect when used as a therapeutic or
preventive treatment. Other examples include the use of
interleukin-12 in an animal model of airway inflammation
[31] or Rolipram in an experimental autoimmune encephalo-
myelitis model [32]. Treatment with atypical antipsychotics
during the prodromal phase has shown promising results in
humans and in animal models of schizophrenia [33,34], but
clearly the early intervention paradigm in psychotic disorders
must be carefully examined during preclinical phases.
Our results showed significant short and long term
memory deficits in the acute KET model consistent with
findings in human schizophrenia and in animal models
[24]. Therapeutic treatment, but not preventive, with
SNP and GTN was able to restore long term memory.
MB pretreatment of KET-injected animals was effective
in long term memory. Interestingly, SNP and MB in-
duced short term memory deficits in control animals.
Other studies on the role of NO donors on spatial working
memory have shown no effects of S-Nitroso-N-acetylpenicil-
lamine in control animals [35], or of molsidomine and SNP
in a novel object recognition test [36], but the highest con-
centration of SNP used in this study was 5 times lower than
in ours. Although it is likely that a lower SNP dose would
not induce short term memory deficits in our control
Figure 3 Object recognition memory. Test phase (30 min after first object exposition) and late test phase (24 hours after first object exposure)
refers respectively to equivalents of short term (A, B and C) and long term memory (D, E and F). SAL+ SNP and SAL +MB showed impaired
short term object recognition memory. KET + SAL and SAL + KET animals showed impaired short and long term memory when compared to SAL
+ SAL (#: p < 0.05). Long term memory improvement was seen in KET animals post-treated with GTN and with SNP, but not on those pretreated.
Long term memory improvement was seen in KET animals pretreated with MB, but not on those post-treated. *: p < 0.05; **: p < 0.01; tr: p = 0.05.
Values presented as mean ± standard error of mean. N = 12 to 14 on each group.
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animals, Bujas-Bobanovic et al. have already reported that
SNP used only in doses higher than 4 mg/kg is able to abol-
ish completely and in a prolonged fashion PCP-induced
ataxia, hyperlocomotion and neuronal activation in several
brain regions of the rat [3]. Low doses of SNP are not able to
cause significant vascular effects in humans [1], but SNP can
improve cerebral dynamics in experimental models [37,38].
Although NO donors may facilitate neurotoxic cascades [39],
there is also reports on oxidative damage prevention [40].
Detailed neuropathological alterations in schizophrenia
models following SNP remain to be investigated.
The preventive antipsychotic-like action of MB has been
documented in a mouse model of schizophrenia using a sin-
gle injection of MK-801 [12], but in our acute KET model
MB was ineffective. MB has been successfully used in the
treatment of depressive symptoms in bipolar patients [41].
These findings agree with reports that NO inhibitors may ex-
hibit antidepressant effects in animal models [42]. MB has
also been used to reverse spatial memory deficits in rats [43],
to improve memory in the amnestic mild cognitive impair-
ment rat model [20], and in our KET model MB pretreat-
ment resulted in long term memory recovery. A possible
mechanism, as explored by Callaway et al. [43], would be
through increased cytochrome c oxidase activity, enabling an
increased metabolic capacity for oxidative energy metabolism
in the brain that would improve memory retention. As a
therapeutic treatment in the KET model, MB did not cause
any memory improvement effect, suggesting that further in-
creased energy metabolism might not be helpful when alter-
ations caused by KET are already on course. In fact, frontal
hypermetabolic pattern in positron emission tomography im-
aging using [18 F]deoxyglucose tracer has been demon-
strated in unmedicated patients with schizophrenia [44] and
in the KETanimal model [45].
Although both GTN and SNP are NO donors, their
therapeutic and preventive effects were dissimilar. Long-
Figure 4 Behaviors in the open field test. GTN, SNP or MB did not show anxiolytic effects in control animals regarding the proportion of their
trajectory spent in the center (A). KET + SAL (B) and SAL + KET (C) were more frequently in the center than SAL + SAL (#: p < 0.04). Decreased
vertical activity was seen in control animals treated with SNP (D) and in KET animals post-treated with SNP (E). Pretreatment did not result in
significant differences in vertical activity (F). *: p < 0.05. Horizontal activity was decreased in control animals treated with SNP (G) during the first
4 min of the open field test (§: p < 0.05). KET + SAL (H) and SAL + KET (I) animals presented with hyperlocomotion during all time points of the
open field test when compared to SAL + SAL (#: p < 0.003). Therapeutic treatment with SNP was able to revert KET-induced hyperlocomotion
(£: p < 0.04 in H). KET + MB showed increased horizontal activity when compared to KET + SNP (¢: p = 0.001). Preventive treatment with SNP
prevented KET-induced hyperlocomotion (£: p < 0.02 in I). GTN + KET ($: p < 0.001) and MB+ KET (¢: p < 0.009) showed increased horizontal activity
when compared to SNP + KET. GTN+ KET showed increased horizontal activity when compared to MB + KET (€: p = 0.03). Values presented as mean ±
standard error of mean. N = 12 to 14 on each group.
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term memory improvement was seen with therapeutic
GTN treatment, but not with the preventive one. GTN
pretreatment in the KET model increased vertical and
horizontal activity, but that was not the case with GTN
post-treatment. Therapeutic and preventive SNP treat-
ment consistently decreased KET-induced hyperlocomo-
tion. In healthy human subjects, GTN treatment does
not change cognitive functions [46]. In the KET model,
which exhibits cognitive deficits [24], NO-related com-
pounds from the therapeutic treatment with SNP and
GTN could improve memory deficit consolidation. Im-
provement of memory acquisition has also been seen in
mice when NO production and neuronal NOS expres-
sion were induced, and this effect was abolished by a
NO inhibitor [47,48]. In addition, neuronal NOS knock-
out mice show impaired cognitive performance [49]. If
SNP or GTN treatments result in alterations in NOS ex-
pression and how that could be related to memory per-
formance remain open questions.
In a previous study, Bujas-Bubanovic et al. [3] reported
that SNP pretreatment of SAL-injected Sprague-Dawley rats
resulted in a trend to decreased ambulation at the beginning
of the open field test when compared to animals injected
only with SAL. In our study using Wistar rats, decreased am-
bulation of SAL-injected animals treated with SNP when
compared to animals treated with SAL was also only seen
during the first 4 min of the open field test. Different
sensitivity depending on strain could explain this tenuous dif-
ference. For instance, the effects of NO inhibition on
reserpine-induced hypolocomotion seem to depend on the
mouse strain used [50].
In the KET model, we noted an anxiolytic effect of
KET when compared to control animals. Such effect was
also reported when KET was used as a treatment in a
model of posttraumatic stress disorder [51], and in anx-
ious depressed patients [52]. Given that anxiety is part
of schizophrenia symptoms [22], the acute KET model is
not the most suitable model to evaluate its expression.
Even with this limitation, we found that NO modulation
was unable to affect anxiety-related parameters in con-
trol or in KET-injected animals. A similar rationale ap-
plies to the sucrose consumption test. While anhedonia
may be a component of schizophrenia symptomatology
[22], KET action as a fast antidepressant [53] would in-
fluence the hedonic state. However, our results suggest
that therapeutic treatment with SNP in KET-injected an-
imals has advantages for mood stability when compared
to GTN and MB post-treatment. Interestingly, symp-
toms of anxiety and depression were also improved in
patients with schizophrenia treated with SNP [1].
Nevertheless, NO inhibitors are frequently used as a
preventive treatment in models of major depression
[54,55]. If the effect of NO inhibitors is the same when
used in a therapeutic scheme remains to be determined.
In the evaluation of cognitive parameters, preventive
treatment with the NO donors molsidomine and S-
Nitroso-N-acetylpenicillamine was successful in the MK-
801 model [35,56]. Meanwhile, pretreatment with either
a NO donor or a NO inhibitor was effective in the apo-
morphine model [36]. In a scenario of massive dopamin-
ergic dysfunction, Gourgiotis et al. show that preventive
use of NO donors and NO inhibitors might share similar
beneficial outcomes on memory deficits due to their ac-
tions on two functionally opposing systems [36]. The
exact neurochemical scenario of a glutamatergic dys-
function followed or anticipated by NO augmentation is
still unknown, but our behavioral analyses favor thera-
peutic NO increases. Despite most studies with animal
models of psychiatric conditions perform their evalua-
tions using the preventive scheme and have thus con-
tributed with valuable findings, in the clinical practice
the therapeutic approach is more frequent. In the acute
KET model, pre and post-treatment with GTN, SNP and
MB were dissimilar in all behavioral instances analyzed,
reassuring the importance of comparing treatment
schemes in light of what is transposable to clinical trials.
Conclusion
In summary, our results using SNP in the acute KET
model of schizophrenia reproduced and expanded the
findings of the preventive effects described for the PCP
model [3]. Also, SNP produced a marked and positive
outcome when used as a therapeutic treatment, as also
recently highlighted by clinical observations [1,2]. The
effects of MB and GTN were more variable, suggesting
that the involvement of NO-cGMP/sGC pathway-related
molecules in schizophrenia is more complex than ini-
tially thought. Additional studies to better understand
the differential mechanisms of preventive and thera-
peutic action of SNP and GTN in animal models may
open new venues for treatment of schizophrenia.
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